Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

CLEAR study meets primary endpoint: Sorin Group

Sorin Group, a global leader in the treatment of cardiovascular diseases, announced today that the CLEAR study has met its primary endpoint.

18 Jun 2010

St. Jude Medical commences enrollment in LAPTOP-HF study

St. Jude Medical, Inc., a global medical device company, today announced the first enrollment in its LAPTOP-HF (Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy) study. The goal of the LAPTOP-HF study is to demonstrate that the new investigational left atrial pressure (LAP) management system safely and effectively improves outcomes in patients with heart failure (HF).

17 Jun 2010

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

A research team from McGill University (Canada) report a beneficial effect on cardiac function in mouse models when implanted monocytes - a type of white blood cell that is part of the immune system - helped preserve cardiac function following a heart attack (myocardial infarction).

17 Jun 2010

Relypsa commences enrollment for RLY5016 Phase 2 study in heart failure patients with chronic kidney disease

Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.

16 Jun 2010

BIOTRONIK announces 10th anniversary of world's first wireless, mobile patient monitoring technology

BIOTRONIK SE & Co KG, the pioneer in wireless remote monitoring technology for patients with cardiac devices, today announced the tenth anniversary of BIOTRONIK Home Monitoring®—the world's first wireless, mobile patient monitoring technology—to be celebrated during Cardiostim in Nice, France.

16 Jun 2010

New public service advertisements to spread preventive medical testing awareness

Men are 24 percent less likely than women to have visited the doctor within the past year, according to new data released today by the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality. In addition, men are about 30 percent more likely than women to be hospitalized for preventable conditions such as congestive heart failure and complications from diabetes, according to new AHRQ data.

16 Jun 2010

ARBs may be linked with increased risk of developing cancer: US scientists

A common class of blood pressure drugs called angiotensin-receptor blockers may be linked with a slightly increased risk of developing cancer, US scientists have found.

16 Jun 2010

BIOTRONIK announces commercial availability of new ProMRI Pacing Systems

BIOTRONIK SE & Co. KG, a leading manufacturer of high-quality implantable cardiac devices and pioneer of wireless remote monitoring technologies, announced today the commercial availability of its new ProMRI Pacing Systems — Evia pacemaker series and Safio pacing leads — providing European patients the first portfolio of bradycardia systems that are compatible with Magnetic Resonance Imaging scans under specific conditions.

15 Jun 2010

Mechanical heart pumps can improve survival among patients with life-threatening heart failure: Thesis

Heart failure is a very common condition: around 200,000 people in Sweden have been diagnosed with the disease. Some patients with life-threatening heart failure can be helped by mechanical heart pumps, reveals a thesis from the University of Gothenburg, Sweden.

15 Jun 2010

FDA grants HeartWare approval for IDE destination therapy study of Ventricular Assist System

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted HeartWare conditional approval to begin enrollment in an Investigational Device Exemption (IDE) destination therapy clinical study for the HeartWare® Ventricular Assist System.

15 Jun 2010

First hospital in Mexico to use GORE HELEX Septal Occluder for transcatheter closure of ASD

W. L. Gore & Associates (Gore) today announced that Instituto Nacional De Cardiologia in Mexico City, Mexico, is the first hospital in the country to use the GORE® HELEX Septal Occluder for the transcatheter closure of an atrial septal defect (ASD). Department Chief, Dr. Carlos Zabal and Dr. Jose Garcia Montes of the Instituto Nacional de Cardiologia, in Mexico City, achieved the milestone procedure in March, 2010.

14 Jun 2010

ARBs increase risk of cancer: Study

University Hospitals Case Medical Center cardiologists have uncovered new research showing an increased risk of cancer with a group of blood pressure medications known as angiotensin-receptor blockers (ARBs).

14 Jun 2010

Phase II study results of riociguat for CTEPH and PAH published online

Bayer HealthCare Pharmaceuticals, Inc. today announced that the study "Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study" was published online this week by the European Respiratory Journal. Results of this study to assess the safety, tolerability and the feasibility of individual dose titration of riociguat were previously presented at the 2009 International Conference of the American Thoracic Society.

11 Jun 2010

Boston Scientific announces event schedule at 17th Cardiostim World Congress

Boston Scientific Corporation today announced the schedule of the Company's key events and sponsored research at the 17th Cardiostim World Congress, June 16 – 19 in Nice, France.

11 Jun 2010

Trevena's scientists present research data on GPCR biased ligands at two scientific conferences

Trevena Inc., a leader in the discovery of G-protein coupled receptor biased ligands, today announced that its scientists are presenting research data at two scientific conferences. These oral presentations highlight Trevena's research demonstrating that ligand bias at the angiotensin II type I receptor translates into differentiable and beneficial cardiovascular pharmacology in vivo.

11 Jun 2010

Remote monitoring and nurse case management combined improve health of Medicare beneficiaries with CHF

Chronic heart failure (CHF) is one of the most common causes of hospitalization for elderly Americans, and is also one of the nation's most costly conditions to treat.

10 Jun 2010

Caregiver's guide on avoiding life-threatening swallowing problems

That's the message of Drs. Roya Sayadi and Joel Herskowitz. They are a wife-husband team from Natick, Massachusetts, who are spreading the word that swallowing problems are everywhere - and they can be deadly!

10 Jun 2010

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced four-year follow-up results from a Phase 3 randomized, open-label, dose-optimization study of SPRYCEL® (dasatinib) in chronic-phase chronic myeloid leukemia (CML-CP) patients resistant or intolerant to Gleevec®* (imatinib mesylate). At four years, for all patients administered SPRYCEL 100 mg once daily, overall survival was 82% (95% CI: 76%-88%) and progression-free survival was 66% (95% CI: 57%-74%).

9 Jun 2010

Clinical guidelines for UC emergency medicine physicians

Though guidelines for best treatment practices are common, they are only partially effective without standardized, routine exposure to them in clinical practice, according to a study conducted by University of Cincinnati emergency medicine researchers.

9 Jun 2010

Researchers compare effectiveness of IB and AMP in high-risk patients

Major amputation is often selected over infrainguinal bypass in patients with severe systemic comorbidities because of a presumed decrease in risk of perioperative morbidity and mortality. To investigate this presumption, researchers from the Division of Vascular and Endovascular Surgery at the Brigham and Women's Hospital in Boston undertook a risk-adjusted comparison of early postoperative morbidity and mortality of high-risk patients undergoing infrainguinal bypass and major amputation.

9 Jun 2010

Heart Failure News and Research

Further Reading

CLEAR study meets primary endpoint: Sorin Group

St. Jude Medical commences enrollment in LAPTOP-HF study

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

Relypsa commences enrollment for RLY5016 Phase 2 study in heart failure patients with chronic kidney disease

BIOTRONIK announces 10th anniversary of world's first wireless, mobile patient monitoring technology

New public service advertisements to spread preventive medical testing awareness

ARBs may be linked with increased risk of developing cancer: US scientists

BIOTRONIK announces commercial availability of new ProMRI Pacing Systems

Mechanical heart pumps can improve survival among patients with life-threatening heart failure: Thesis

FDA grants HeartWare approval for IDE destination therapy study of Ventricular Assist System

First hospital in Mexico to use GORE HELEX Septal Occluder for transcatheter closure of ASD

ARBs increase risk of cancer: Study

Phase II study results of riociguat for CTEPH and PAH published online

Boston Scientific announces event schedule at 17th Cardiostim World Congress

Trevena's scientists present research data on GPCR biased ligands at two scientific conferences

Remote monitoring and nurse case management combined improve health of Medicare beneficiaries with CHF

Caregiver's guide on avoiding life-threatening swallowing problems

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Clinical guidelines for UC emergency medicine physicians

Researchers compare effectiveness of IB and AMP in high-risk patients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News